1.Alexander, LN, Seward, JF, Santibanez, TA, et al.Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004;292:1696–1701.
2.Prevots, DR, Burr, RK, Sutter, RW, Murphy, TV. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-5): 1–22.
3.Update: Outbreak of poliomyelitis—Dominican Republic and Haiti, 2000-2001. MMWR Morb Mortal Wkly Rep 2001;50:855–856.
4.Khetsuriani, N, Prevots, DR, Quick, L, et al.Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis 2003;188:1845–1852.
5.Poliovirus infections in four unvaccinated children—Minnesota, August-October 2005. MMWR Morb Mortal Wkly Rep 2005;54:1053–1055.
6.ACIP issues recommendations for vaccines and immune globulins in immunocompromised persons. Advisory Committee on Immunization Practices. Am Fam Physician 1993;48:337–340.
7.Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996;45(RR-12): 1–35.
8.Takahashi, M, Otsuka, T, Okuno, Y, Asano, Y, Yazaki, T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2:1288–90.
9.Tsolia, M, Gershon, AA, Steinberg, SP, Gelb, L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr 1990;116:184–189.
10.Salzman, MB, Sharrar, RG, Steinberg, S, LaRussa, P. Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr 1997;131:151–154.
11.Bruneil, PA, Argaw, T. Chickenpox attributable to a vaccine virus contracted from a vaccine with zoster. Pediatrics 2000;106: E28.
12.Kappagoda, C, Shaw, P, Burgess, M, Botham, S, Cramer, L. Varicella vaccine in non-immune household contacts of children with cancer or leukaemia. J Paediatr Child Health 1999;35:341–345.
13.Diaz, PS, Au, D, Smith, S, et al.Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics 1991;87:166–170.
14.Gershon, AA. Vaccines. 4th ed. Philadelphia: WB Saunders; 2003.
15.Gershon, AA, Steinberg, SP. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Infect Dis 1990;161:661–666.
16.American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update. Pediatrics 2000;105:136–141.
17.Watson, JC, Hadler, SC, Dykewicz, CA, Reef, S, Phillips, L. Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998;47(RR-8): 1–57.
18.Millson, DS. Brother-to-sister transmission of measles after measles, mumps, and rubella immunisation. Lancet 1989;1:271.
19.Monafo, WJ, Haslam, DB, Roberts, RL, Zaki, SR, Bellini, WJ, Coffin, CM. Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr 1994;124:273–276.
20.Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep 1996;45:603–606.
21.Sawada, H, Yano, S, Oka, Y, Togashi, T. Transmission of Urabe mumps vaccine between siblings. Lancet 1993;342:371.
22.Nakayama, T, Oka, S, Komase, K, et al.The relationship between the mumps vaccine strain and parotitis after vaccination. J Infect Dis 1992;165:186–187.
23.Exposure to mumps during air travel—United States, April 2006. MMWR Morb Mortal Wkly Rep 2006;55:401–402.
24.Mumps epidemic—Iowa, 2006. MMWR Morb Mortal Wkly Rep 2006;55:366–368.
25. FluMist [package insert]. Gathersburg, MD: Medlmmune Vaccines, Inc.; 2006.
26.Harper, SA, Fukuda, K, Cox, NJ, Bridges, CB. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52(RR-13): 1–8.
27.Vesikari, T. Randomized, double-blind, placebo-controlled trial of the safety, transmissibility and phenotypic stability of a live, attenuated, cold-adapted influenzavirus vaccine (CAIV-T) in children attending day care. In: Program and abstracts of the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). 2001:262. Abstract G-450.
28.Talbot, TR, Crocker, DD, Peters, J, et al.Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol 2005;26:494–500.
29.Izurieta, HS, Haber, P, Wise, RP, et al.Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005;294:2720–2725.
30.Smith, NM, Bresee, JS, Shay, DK, Uyeki, TM, Cox, NJ, Strikas, RA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 2006;55(RR-10): 1–42.
31.Sepkowitz, KA. How contagious is vaccinia? N Engl J Med 2003;348:439–446.
32.Secondary and tertiary transfer of vaccinia virus among U.S. military personnel—United States and worldwide, 2002-2004. MMWR Morb Mortal Wkly Rep 2004;53:103–105.
33.Wharton, M, Strikas, RA, Harpaz, R, et al.Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003;52(RR-7):1–16.
34.Casey, C, Vellozzi, C, Mootrey, GT, et al.Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm Rep 2006;55(RR-1):1–16.
35.Lane, JM, Fulginiti, VA. Transmission of vaccinia virus and rationale for measures for prevention. Clin Infect Dis 2003;37:281–284.